EICHORCondition: Limited-stage Small Cell Lung Cancer (LS-SCLC) · Sponsor: Shanghai Junshi Bioscience Co., Ltd.
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy. Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death protein-1 (PD-1). Neither drug is approved for treatment of This combination regimen is investigational in limited stage-small cell lung cancer in any country.
This description comes directly from the study's public registry record.
kui zhang, Project Directer · 08618168028925 · kui_zhang@junshipharma.com
Kinga Kovacs, Senior Project Leader · + 31 6 45974346 · Kinga.Kovacs@parexel.com
Always discuss trial participation with your own doctor first.
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Recruiting |
| Xiangya Hospital Central South University | Changsha, Hunan, China | Recruiting |
| The Second Affiliated Hospital of Nanchang University | Nanchang, Jiangxi, China | Recruiting |
| The First Hospital of China Medical University | Shenyang, Liaoning, China | Recruiting |
| Shandong Cancer Hospital & Institute | Jinan, Shandong, China | Recruiting |
| Anyang Tumor Hospital | Anyang, China | Recruiting |
| Beijing Cancer Hospital | Beijing, China | Not Yet Recruiting |
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, China | Recruiting |
| Jilin Cancer Hospital | Changchun, China | Recruiting |
| Hunan Cancer Hospital | Changsha, China | Recruiting |
| Sichuan cancer hospital | Chengdu, China | Not Yet Recruiting |
| Chongqing University Cancer Hospital | Chongqing, China | Recruiting |
+ 64 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06095583